Background: Fraction of exhaled nitric oxide (FENO) and blood eosinophil count (B-Eos) values, markers of local and systemic eosinophilic inflammation, respectively, are increased in asthmatic patients. Little is known about the relation of these markers to reported wheeze and asthma events in a random population sample. Objectives: We sought to determine the individual and independent values of B-Eos and FENO in relation to wheeze, asthma diagnosis, and asthma events in a cross-sectional study. 3 ) values rendered an adjusted odds ratio of 4.5 of having wheeze, 5.1 of having asthma, 5.4 for asthma attacks, and 2.9 for asthma-related ED visits compared with normal FENO (<25 ppb) and B-Eos (<300 cells/mm
Asthma is characterized by chronic airway inflammation, variable airway obstruction, and airway hyperresponsiveness. 1 Inflammation is a major component of asthma, and medication to control asthma is primarily anti-inflammatory. Nonetheless, it is only during the past decade that inflammometry (ie, measurement of inflammation to adjust anti-inflammatory therapy) has been introduced. 2 The fraction of exhaled nitric oxide (FENO) is a local marker of airways inflammation, primarily that triggered by IL-4 and IL-13. 3 Measurement of FENO is increasingly used in clinical practice, and clinical guidelines on the use of FENO have recently been published by the American Thoracic Society (ATS). 4 Systemic eosinophilic inflammation, which is measured as blood eosinophil count (B-Eos) or serum eosinophil cationic protein (ECP) values, is also seen in asthmatic patients. 5, 6 Eosinophilia is primarily triggered by IL-5. 7 Systemic eosinophilic inflammation is often regarded as a spillover from the inflamed airways. However, only moderate correlations have been reported between the 2 components, 8 and this view is now being challenged by a model in which systemic inflammation plays an independent role in patients with asthma and other respiratory diseases. 3, 9, 10 This new hypothesis is supported by data from studies showing that systemic inflammation is not always reduced by inhaled corticosteroids 11, 12 and that systemic therapies, such as leukotriene receptor antagonists, might be more effective in reducing systemic inflammatory markers. 13, 14 Furthermore, biological treatments directed at blocking IL-5 effectively decrease the signs of systemic inflammation, as measured by B-Eos values, but does not change FENO values, 15 whereas anti-IL-13 treatment reduces FENO values without decreasing B-Eos values. 16 Therefore it is reasonable to suggest that assessing both local and systemic eosinophilic inflammation in asthmatic patients would provide complementary information.
The aim of the present study was to assess the levels of local (FENO) and systemic (B-Eos) T H 2 cytokine-driven inflammation in subjects from the US National Health and Nutrition Examination Survey (NHANES) 17 and to investigate the relation between these 2 inflammatory components in respect to selfreported wheeze, physician-diagnosed asthma, asthma attacks, and emergency department (ED) visits for asthma.
METHODS

Ethics statement
The Ethics Review Board of the National Center for Health Statistics Research approved all protocols. All participants provided written informed consent.
Study population
The study included 12,408 participants aged 6 to 80 years from the NHANES 2007-2008 and NHANES 2009-2010 on whom exhaled nitric oxide (NO) measurements and blood differential counts had been performed. Through the use of a complex probability cluster design, NHANES collects nationally representative cross-sectional data on the health status of the civilian, noninstitutionalized US population (http://www.cdc.gov/nchs/ nhanes.htm). Standardized health measurements were performed in mobile examination centers.
Exhaled NO
FENO values were measured with an electrochemical analyzer (NIOX MINO; Aerocrine AB, Solna, Sweden) at an expiratory flow rate of 50 mL/s in accordance with ATS/European Respiratory Society recommendations. 18 The mean of 2 reproducible FENO measurements (within 2 ppb if levels were <30 ppb or within 10% if levels were >30 ppb) was taken as the final result.
Two measurements of less than the detection limit of the device (<5 ppb) were considered reproducible and given an arbitrary value of 3.5 ppb (1180 subjects). Two measurements of greater than the detection limit of the device (>300 ppb) were also considered reproducible and given an arbitrary value of 301 ppb (1 subject).
In accordance with the ATS clinical guidelines on FENO measurement, 4 we have designated levels of less than 20 ppb (if <12 years of age) or less than 25 ppb as normal FENO levels (if > _12 years of age), levels of 20 or greater but less than 35 ppb (if <12 years of age) and levels of 25 or greater but less than 50 ppb (if > _12 years of age) as intermediate FENO levels, and levels of 35 ppb or greater (if <12 years of age) or 50 ppb or greater (if > _12 years of age) as high FENO levels. Current asthma and current wheeze Current wheeze was defined as self-reported wheezing or whistling in the chest during the last 12 months. Current asthma was defined as self-reported physician-diagnosed asthma at any time of life together with a positive answer to the following question: ''Do you still have asthma?'' Asthma attacks and asthma-related ED visits during the last 12 months were self-reported.
B-Eos
Hay fever
Self-reported hay fever episodes in the past 12 months were considered to imply atopy. 17 
Current use of inhaled or oral corticosteroids
Self-reported use of inhaled corticosteroids (ICSs) or oral corticosteroids (OCSs) during the last 2 days before exhaled NO measurements was regarded as current use of corticosteroids.
Smoking history
Questions regarding cigarette use were only administered to participants aged 20 years and older. We assumed that younger participants were never smokers. 17 A person was considered to be a never smoker if he or she had smoked less than 100 cigarettes in his or her entire life. Subjects reporting ever smoking at least 100 cigarettes during their lifetimes were classified, based on self-reported current smoking, as exsmokers or current smokers.
Body mass index
Height and weight were measured with digital stadiometers and scales, as described on the NHANES Web site (http://www.cdc.gov/nchs/nhanes.htm). Body mass index (BMI) was calculated as weight (kilograms) divided by height squared (square meters).
Statistical analyses
All the statistical analyses were conducted with STATA 12.1 software (StataCorp, College Station, Tex). Pearson correlation was used to study the relation between log-transformed FENO and B-Eos values. Pearson x 2 test statistics and associated probabilities (P values) were calculated to evaluate differences among observed percentages across normal-intermediate-high categories of FENO and B-Eos values (Table I and see Tables E1 and E2 in this article's Online Repository at www.jacionline.org). Logistic regression models, having current asthma, wheeze, asthma attacks, or asthma-related ED visits as outcomes and FENO and B-Eos values as determinants, were used to calculate odds ratios and CIs for prevalence rates of current asthma, wheeze, asthma attacks, or asthma-related ED visits (Table II and see Tables  E3 and E4 in this article's Online Repository at www.jacionline.org). FENO and B-Eos values were included in the regression models a priori. A similar model with the same outcomes (current asthma, wheeze, asthma attacks, or asthma-related ED visits) and a combination of FENO and B-Eos value categories as a determinant was used in Table III and Table E5 in this article's Online Repository at www.jacionline.org. These multiple logistic regression models included adjustments for age, sex, BMI, hay fever, current smoking, and recent use of inhaled or oral corticosteroids. Holm adjustments for multiple comparisons were also reported in the models described in Tables III and  E5 . Because atopy is related to FENO values, 21 a multiple logistic regression model not adjusted for hay fever (used as proxy for atopy in this study) was also reported (see Table E5 ). A P value of less than .05 was considered statistically significant.
RESULTS
A total of 12,408 subjects have performed FENO measurements and blood differential counts and were included in the study. The characteristics of these subjects are presented in Table IV .
There was a weak but statistically significant correlation between the FENO and B-Eos values (Pearson r 5 0.22, P < .001). The explanatory value (R 2 ) was 4.0%. FENO values, according to different (normal-intermediate-high) B-Eos value categories, are depicted in Fig 1, and the explanatory value (R 2 ) of this model was 4.6%. The explanatory value was slightly higher when looking at the subgroups of subjects with current asthma (n 5 994, R 2 5 0.13, P < .001) or wheeze (n 5 1519, R 2 5 0.09, P < .001). The prevalence of current asthma and wheeze increased progressively with increased FENO values (Table I) . A similar increase in current asthma and wheeze was observed with increased B-Eos values (all P < .001, Table I ). Also, the prevalence of asthma attacks and asthma-related ED visits increased with higher FENO and B-Eos values, respectively (Table I) . These results were consistent when separately analyzing children (see Table E1 ) and adults (see Table E2 ).
When looking at the 2 markers in combination, the prevalence of current asthma increased with increased FENO and B-Eos values from 6.2% in the group with normal FENO and B-Eos values to 33.3% in the group with high FENO and B-Eos values (Fig 2) . Having intermediate or high FENO values and intermediate or high B-Eos values was independently associated with having asthma, wheeze, and asthma attacks (Table II) . However, only intermediate and high B-Eos values were independently associated with asthma-related ED visits. Additional risk factors were high BMI, hay fever, and current smoking (Table II) . Similar relations were found in children (see Table E3 ) and adults (see Table E4 ). No significant interactions with age (children vs adults) were found when analyzing the relation between having intermediate and high FENO values or intermediate and high B-Eos values and wheezing, asthma, and asthma events.
An increased probability of having current asthma and wheeze was found with increasing FENO values by different strata of B-Eos values (Fig 3) , with the highest probability in the group with high B-Eos values. A significantly increased probability of asthma attacks was found with increased FENO values only in subjects with intermediate or high B-Eos values, whereas a significantly increased probability of asthma-related ED visits was found only in subjects with high B-Eos values.
The risk (odds ratio) of having wheeze or current asthma increased approximately 5-fold in subjects with both high FENO and high B-Eos values compared with subjects with normal FENO and normal B-Eos values after adjustment for other risk factors (Table III and see Table E5 without adjustment for hay fever). The corresponding odds ratios for asthma attacks and (Table III) . A consistent effect of having both high FENO and high B-Eos values on all the asthma variables was seen after exclusion of subjects taking ICSs or OCSs and after the additional exclusion of subjects reporting hay fever. Furthermore, a consistent effect on wheeze was seen after excluding current asthma (Fig 4) .
DISCUSSION
The main finding from this study in a large population was that FENO and B-Eos values were each independently associated with current asthma, wheeze, and asthma attacks, as well as being associated in an additive manner. Our data support the view that these 2 markers cannot be used interchangeably but should be used in combination. However, it must be recognized that this is a population-based study with the main purpose of identifying new information regarding these 2 inflammatory components and not a study for determining the diagnostic accuracy of these methods. Such a study should be performed in a more relevant population, such as in subjects undergoing clinical investigations because of suspected asthma.
In the present study, asthma and wheeze were 3 times more prevalent among subjects with high exhaled NO values than among subjects with normal values, and the prevalence was increased to a similar level among those with high B-Eos values. Several studies have previously found such associations for each of these markers separately, 22 but to our knowledge, no earlier study has evaluated the additive predictive value of systemic eosinophil markers and exhaled NO values.
One reason why few have tested the predictive value of the combination of FENO and B-Eos might be that these markers are generally considered to measure the same inflammatory component of asthma, usually defined as ''eosinophilic airway inflammation.'' 4 However, in the present study the correlation between FENO and B-Eos values was weak, with an explanatory value of only approximately 4%, which is in line with the previously reported weak-to-moderate correlations between FENO and eosinophil values in blood or sputum 8, 23 or between blood and sputum eosinophil values. 24 This, together with the clear-cut additive effect of these 2 markers on the risk for asthma, wheeze, and asthma attacks in our study, indicates that they represent 2 different inflammatory pathways with separate trigger mechanisms.
Interestingly, increased blood eosinophil values were more important in relation to asthma-related ED visits in this material, which is in line with the recent findings of severe asthma exacerbation reductions in subjects with severe eosinophilic asthma 25 receiving anti-IL-5 treatment, which primarily targets the systemic eosinophilic inflammation. A previous study performed in children reported a relation between serum ECP values and asthma attacks, 26 whereas a Dutch registry study reported a relation between asthma attacks with eosinophilia and mortality. 27 FENO signals local IL-4/IL-13-mediated mechanisms in the bronchial mucosa that are primarily triggered by aeroallergen exposure. 3 An increase in FENO values seems to precede moderate, but not severe, asthma exacerbations. 28 We have recently reported that guiding anti-inflammatory treatment in asthma based on FENO measurement resulted in a reduction of moderate, but not severe, exacerbations. 29 Severe exacerbations are primarily related to viral infections. 30 Increased baseline sputum eosinophil values were related to more severe symptoms in respect to experimental rhinovirus infection, 31 which might support our findings on the relation between increased B-Eos values and asthma-related ED visits.
The general view has been that eosinophilic asthma can be identified by at least 1 of the following: increased FENO, increased sputum eosinophil, or increased blood eosinophil values. 18, 25 Our results indicate that this view is valid only at the group level and not at the individual level. At the individual level, a combination of markers is preferred. Furthermore, from recent asthma studies in which the clinical effect of new biological drugs has been evaluated, particularly anti-IL-5 15 and anti-IL-13, 16 it is evident that exhaled NO and blood eosinophil values signal different cytokine mechanisms. 3 Blood eosinophilia is primarily driven by IL-5 7 and might be triggered also, for example, by subchronic or persistent rhinovirus infections 32 or in connection to chronic rhinosinusitis with or without polyposis 33 in addition to aeroallergen exposure.
Taken together, both local and systemic T H 2 cytokine-driven mechanisms, partly with different triggers, seem to be involved in ''eosinophilic'' asthma, suggesting a ''double-hit'' mechanism for the development of respiratory symptoms and asthma. One advantage of FENO and B-Eos measurements is that these methods are relatively inexpensive and that the sampling causes less discomfort for the patients than other methods of assessing inflammation, such as induced sputum or bronchoscopy. During recent years, there has been a great interest in identifying different phenotypes of asthma to develop more targeted therapeutic interventions. 33 Our data indicate that using FENO and B-Eos measurements in combination might be a cost-effective way of gathering phenotypic information in asthmatic patients 34 and that the systemic eosinophilic component might be more related to severe asthma exacerbations, as discussed above.
Even though the combination of high FENO and B-Eos values was strongly related to current asthma, wheeze, and asthma attacks, it should be noted that a significant proportion of subjects in this group reported neither. However, it is possible that asymptomatic subjects with the combination of high FENO and high B-Eos values constitute a group with a very high risk of asthma because increased B-Eos values have been related to future development of asthma in a longitudinal study 35 and increased serum ECP levels were related to the incidence of asthma in a population of patients with allergic rhinitis. 36 Similarly, increased FENO values have been shown to indicate increased risk of asthma or wheeze. 37 ,38 A possible limitation of the present study is that the biomarkers used are both markers of the eosinophilic type of inflammation, and therefore other inflammatory patterns, such as neutrophilic inflammation, would not be identified. However, in the general asthmatic population the phenotype characterized by eosinophilic activation predominates. 33 Furthermore, the main result regarding the independent and additive value of the 2 biomarkers in detecting asthma or wheeze would probably not have been affected by the presence of noneosinophilic asthma. No data on IgE sensitization are available for the subjects included in the present study. However, the additive value of FENO and B-Eos measurements for predicting asthma or wheeze was confirmed, even after we excluded subjects with reported hay fever as a proxy for IgE sensitization.
In conclusion, information from this large population study shows that it might be advantageous to assess both local inflammation in the airways (FENO) and systemic eosinophilic inflammation (eg, B-Eos) to identify subjects with wheeze and asthma and patients at risk of asthma exacerbations. Our findings support the view that both local and systemic T H 2 cytokine-driven mechanisms are important for the development of respiratory symptoms and clinical asthma, but the clinical use of the combination of these markers warrants further study.
Clinical implications: Local and systemic T H 2 cytokine-driven mechanisms independently trigger the development of respiratory symptoms and clinical asthma. The clinical importance of assessing both these components for individualizing treatment decisions warrants further study. 
